


AMENDMENTS TO THE CLAIMS:

Amend the claims as follows.

Claims 1-79. (canceled).

80. (Previously Presented) A compound of the formula:



wherein:

Cy is independently a cyclcyl group;

Q¹ is independently a covalent bond or cyclcyl leader group;

the piperazin-1,4-diyl group is optionally substituted;

J¹ is independently a covalent bond or -C(=O)- ;

J² is independently -C(=O)- or -S(=O)₂- ;

Q² is independently an acid leader group;

wherein:

Cy is independently:

C₃₋₂₀carbocyclcyl,

C₃₋₂₀heterocyclcyl, or

C₅₋₂₀aryl;

and is optionally substituted;

Q¹ is independently:

a covalent bond;

C₁₋₇alkylene; or

C₁₋₇alkylene-X-C₁₋₇alkylene, -X-C₁₋₇alkylene, or C₁₋₇alkylene-X-,

wherein X is -O- or -S-;

and is optionally substituted;

Q² is independently:

C₄₋₈alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or:

Q² is independently:

C₅₋₂₀arylene;

C₅₋₂₀arylene-C₁₋₇alkylene;

C₁₋₇alkylene-C₅₋₂₀arylene; or,

C₁₋₇alkylene-C₅₋₂₀arylene-C₁₋₇alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof.

81. (Previously Presented) A compound according to claim 80, wherein the piperazin-1,4-diyl group is unsubstituted or substituted at one or more the 2-, 3-, 5-, and 6-positions with C₁₋₄alkyl.

82. (Previously Presented) A compound according to claim 80, wherein: J^1 is a covalent bond; and J^2 is $-C(=O)-$.

83. (Previously Presented) A compound according to claim 80, wherein: J^1 is $-C(=O)-$; and J^2 is $-C(=O)-$.

84. (Previously Presented) A compound according to claim 80, wherein: J^1 is a covalent bond; and J^2 is $-S(=O)_2-$.

85. (Previously Presented) A compound according to claim 80, wherein Q^1 is independently: a covalent bond; or a cyclyl leader group; and is optionally substituted.

86. (Previously Presented) A compound according to claim 80, wherein Q^1 is independently a cyclyl leader group, and is optionally substituted.

87. (Previously Presented) A compound according to claim 80, wherein Q^1 is independently C_{1-7} alkylene, and is optionally substituted.

88. (Previously Presented) A compound according to claim 80, wherein: Q^1 is independently C_{1-7} alkylene, and is optionally substituted; J^1 is independently a covalent bond; J^2 is independently $-C(=O)-$.

89. (Previously Presented) A compound according to claim 80, wherein: Q¹ is independently C₁₋₇alkylene, and is optionally substituted; J¹ is independently -C(=O)-; J² is independently -C(=O)-.

90. (Previously Presented) A compound according to claim 80, wherein: Q¹ is independently C₁₋₇alkylene, and is optionally substituted; J¹ is independently a covalent bond; J² is independently -S(=O)₂-.

91. (Previously Presented) A compound according to claim 80, wherein: Q¹ is independently C₁₋₇alkylene, and is optionally substituted; J¹ is independently -C(=O)-; J² is independently -S(=O)₂-.

92. (Previously Presented) A compound according to claim 80, wherein Q¹ is independently C₁₋₃alkylene, and is optionally substituted.

93. (Previously Presented) A compound according to claim 80, wherein Q¹ is independently : C₁₋₇alkylene-X-C₁₋₇alkylene, -X-C₁₋₇alkylene, or C₁₋₇alkylene-X-; wherein X is -O- or -S-; and is optionally substituted.

94. (Previously Presented) A compound according to claim 80, wherein Q¹ is independently :C₁₋₃alkylene-X-C₁₋₃alkylene, -X-C₁₋₃alkylene, or C₁₋₃alkylene-X-; wherein X is -O- or -S-; and is optionally substituted.

95. (Previously Presented) A compound according to claim 80, wherein substituents on Q¹, if present, are independently: halo, hydroxy, ether, C₅₋₂₀aryl, acyl, amino, amido, acylamido, or oxo.

96. (Previously Presented) A compound according to claim 80, wherein substituents on Q¹, if present, are independently: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH₂, -CONH₂, or =O.

97. (Previously Presented) A compound according to claim 80, wherein Q¹, if other than a covalent bond, is unsubstituted.

98. (Previously Presented) A compound according to claim 80, wherein Q¹ is independently a covalent bond.

99. (Previously Presented) A compound according to claim 80, wherein: Q¹ is independently a covalent bond; J¹ is independently a covalent bond; J² is independently -C(=O)-.

100. (Previously Presented) A compound according to claim 80, wherein: Q¹ is independently a covalent bond; J¹ is independently -C(=O)-; J² is independently -C(=O)-

101. (Previously Presented) A compound according to claim 80, wherein: Q^1 is independently a covalent bond; J^1 is independently a covalent bond; J^2 is independently $-S(=O)_2-$.

102. (Previously Presented) A compound according to claim 80, wherein: Q^1 is independently a covalent bond; J^1 is independently $-C(=O)-$; J^2 is independently $-S(=O)_2-$.

103. (Previously Presented) A compound according to claim 80, wherein Q^2 is independently: C_{4-8} alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

104. (Previously Presented) A compound according to claim 80, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

105. (Previously Presented) A compound according to claim 88, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

106. (Previously Presented) A compound according to claim 89, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

107. (Previously Presented) A compound according to claim 90, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

108. (Previously Presented) A compound according to claim 91, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

109. (Previously Presented) A compound according to claim 99, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

110. (Previously Presented) A compound according to claim 100, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

111. (Previously Presented) A compound according to claim 101, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

112. (Previously Presented) A compound according to claim 102, wherein Q^2 is independently a saturated aliphatic C_{4-8} alkylene group.

113. (Previously Presented) A compound according to claim 80, wherein Q^2 is independently a saturated linear C_{4-8} alkylene group.

114. (Previously Presented) A compound according to claim 80, wherein Q^2 is independently selected from: $-(CH_2)_5-$; $-(CH_2)_6-$; $-(CH_2)_7-$; $-(CH_2)_8-$; $-CH(CH_3)CH_2CH_2CH_2CH_2-$; $-CH_2CH_2CH_2CH_2CH(CH_3)-$; $-CH_2CH_2CH_2CH=CH-$; and, $-CH_2CH_2CH_2CH_2CH=CH-$.

115. (Previously Presented) A compound according to claim 80, wherein Q^2 is independently selected from: $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$, and $-(CH_2)_8-$.

116. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently: C_{5-20} arylene; C_{5-20} arylene- C_{1-7} alkylene; C_{1-7} alkylene- C_{5-20} arylene; C_{1-7} alkylene- C_{5-20} arylene- C_{1-7} alkylene; or, and is optionally substituted; and has a backbone length of at least 4 atoms.

117. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently: C_{5-20} arylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

118. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently: C_{5-20} arylene- C_{1-7} alkylene; C_{1-7} alkylene- C_{5-20} arylene;

C_{1-7} alkylene- C_{5-20} arylene- C_{1-7} alkylene; or, and is optionally substituted; and has a backbone length of at least 4 atoms.

119. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently: C_{5-6} arylene- C_{1-7} alkylene; C_{1-7} alkylene- C_{5-6} arylene; or, C_{1-7} alkylene- C_{5-6} arylene- C_{1-7} alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

120. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently: phenylene- C_{1-7} alkylene; C_{1-7} alkylene-phenylene; or, C_{1-7} alkylene-phenylene- C_{1-7} alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

121. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

122. (Previously Presented) A compound according to claim 88, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

123. (Previously Presented) A compound according to claim 89, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-

methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

124. (Previously Presented) A compound according to claim 90, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

125. (Previously Presented) A compound according to claim 91, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

126. (Previously Presented) A compound according to claim 99, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

127. (Previously Presented) A compound according to claim 100, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

128. (Previously Presented) A compound according to claim 101, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.


129. (Previously Presented) A compound according to claim 102, wherein Q^2 , is independently: methylene-phenylene; ethylene-phenylene; phenylene-methylene; phenylene-ethylene; phenylene-ethenylene; methylene-phenylene-methylene; methylene-phenylene-ethylene; methylene-phenylene-ethenylene; ethylene-phenylene-methylene; ethylene-phenylene-ethylene; ethylene-phenylene-ethenylene; and is optionally substituted; and has a backbone length of at least 4 atoms.

130. (Previously Presented) A compound according to claim 120, wherein the phenylene linkage is meta or para.


131. (Previously Presented) A compound according to claim 120, wherein the phenylene linkage is meta.

132. (Previously Presented) A compound according to claim 120, wherein the phenylene linkage is para.

133. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently:



134. (Previously Presented) A compound according to claim 80, wherein Q^2 , is independently:



135. (Previously Presented) A compound according to claim 80, wherein Q^2 is substituted.

136. (Previously Presented) A compound according to claim 80, wherein substituents on Q², if present, are independently: (1) ester; (2) amido; (3) acyl; (4) halo; (5) hydroxy; (6) ether; (7) substituted or unsubstituted C₁₋₇alkyl (8) substituted or unsubstituted C₅₋₂₀aryl; (9) sulfonyl; (10) sulfonamido; (11) amino; (12) morpholino; (13) nitro; and (14) cyano.

137. (Previously Presented) A compound according to claim 80, wherein substituents on Q², if present, are independently:

- (1) -C(=O)OMe, -C(=O)OEt, -C(=O)OPr, -C(=O)OiPr, -C(=O)ONBu, -C(=O)OsBu, -C(=O)OiBu, -C(=O)OtBu, -C(=O)ONPe; -C(=O)OCH₂CH₂OH, -C(=O)OCH₂CH₂OMe, -C(=O)OCH₂CH₂OEt;
- (2) -(C=O)NH₂, -(C=O)NMe₂, -(C=O)NEt₂, -(C=O)N(iPr)₂, -(C=O)N(CH₂CH₂OH)₂;
- (3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;
- (4) -F, -Cl, -Br, -I;
- (5) -OH;
- (6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh; -OCF₃, -OCH₂CF₃; -OCH₂CH₂OH, -OCH₂CH₂OMe, -OCH₂CH₂OEt; -OCH₂CH₂NH₂, -OCH₂CH₂NMe₂, -OCH₂CH₂N(iPr)₂; -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-I;
- (7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe; -CF₃, -CH₂CF₃; -CH₂CH₂OH, -CH₂CH₂OMe, -CH₂CH₂OEt; -CH₂CH₂NH₂, -CH₂CH₂NMe₂, -CH₂CH₂N(iPr)₂; -CH₂-Ph;
- (8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;
- (9) -SO₂Me, -SO₂Et, -SO₂Ph;
- (10) -SO₂NH₂, -SO₂NMe₂, -SO₂NEt₂;

(11) -NMe₂, -NEt₂;

(12) morpholino;

(13) -NO₂; and

(14) -CN.

138. (Previously Presented) A compound according to claim 80, wherein Q² is unsubstituted.

139. (Previously Presented) A compound according to claim 80, wherein Q² has a backbone of at least 5 atoms.

140. (Previously Presented) A compound according to claim 80, wherein Q² has a backbone of at least 6 atoms.

141. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₃₋₂₀carbocyclyl; and is optionally substituted.

142. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₃₋₂₀carbocyclyl derived from one of the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopentene, cyclohexene, norbornane, adamantane, cyclopentanone, and cyclohexanone; and is optionally substituted.

142. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₃₋₂₀heterocyclyl; and is optionally substituted.

144. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₃₋₂₀heterocyclyl derived from one of the following: piperidine, azepine, tetrahydropyran, morpholine, azetidine, piperazine, imidazoline, piperazinedione, and oxazolinone; and is optionally substituted.

145. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₅₋₂₀aryl; and is optionally substituted.

146. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

147. (Previously Presented) A compound according to claim 105, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

148. (Previously Presented) A compound according to claim 106, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

149. (Previously Presented) A compound according to claim 107, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

150. (Previously Presented) A compound according to claim 108, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

151. (Previously Presented) A compound according to claim 109, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

152. (Previously Presented) A compound according to claim 110, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

153. (Previously Presented) A compound according to claim 111, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

154. (Previously Presented) A compound according to claim 112, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

155. (Previously Presented) A compound according to claim 122, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

156. (Previously Presented) A compound according to claim 123, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

157. (Previously Presented) A compound according to claim 124, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

158. (Previously Presented) A compound according to claim 125, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

159. (Previously Presented) A compound according to claim 126, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

160. (Previously Presented) A compound according to claim 127, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

161. (Previously Presented) A compound according to claim 128, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

162. (Previously Presented) A compound according to claim 129, wherein Cy is independently C₅₋₂₀carboaryl or C₅₋₂₀heteroaryl; and is optionally substituted.

163. (Previously Presented) A compound according to claim 80, wherein Cy is independently C₅₋₂₀aryl derived from one of the following: benzene, pyridine, furan, indole, pyrrole, imidazole, pyrimidine, pyrazine, pyridazine, naphthalene, quinoline, indole, benzimidazole, benzothiofuran, fluorene, acridine, and carbazole; and is optionally substituted.

164. (Previously Presented) A compound according to claim 80, wherein Cy is independently an optionally substituted phenyl group.









165. (Previously Presented) A compound according to claim 80, wherein Cy is optionally substituted with one or more substituents selected from:







- (1) ester;
- (2) amido;
- (3) acyl;
- (4) halo;
- (5) hydroxy;
- (6) ether;
- (7) substituted or unsubstituted C₁₋₇alkyl;
- (8) substituted or unsubstituted C₅₋₂₀aryl;
- (9) sulfonyl;
- (10) sulfonamido;
- (11) amino;
- (12) morpholino;
- (13) nitro; and
- (14) cyano.







166. (Previously Presented) A compound according to claim 80, wherein Cy is optionally substituted with one or more substituents selected from:








- (1) -C(=O)OMe, -C(=O)OEt, -C(=O)OPr, -C(=O)O(iPr), -C(=O)O(nBu),
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe); -C(=O)OCH₂CH₂OH, -
C(=O)OCH₂CH₂OMe, -C(=O)OCH₂CH₂OEt;
- (2) -(C=O)NH₂, -(C=O)NMe₂, -(C=O)NEt₂, -(C=O)N(iPr)₂, -(C=O)N(CH₂CH₂OH)₂;
- (3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;
- (4) -F, -Cl, -Br, -I;
- (5) -OH;
- (6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh; -OCF₃, -OCH₂CF₃; -OCH₂CH₂OH, -
OCH₂CH₂OMe, -OCH₂CH₂OEt; -OCH₂CH₂NH₂, -OCH₂CH₂NMe₂, -OCH₂CH₂N(iPr)₂; -
OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-I;
- (7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe; -CF₃, -CH₂CF₃; -CH₂CH₂OH,
-CH₂CH₂OMe, -CH₂CH₂OEt; -CH₂CH₂NH₂, -CH₂CH₂NMe₂, -CH₂CH₂N(iPr)₂; -CH₂-Ph;
- (8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;
- (9) -SO₂Me, -SO₂Et, -SO₂Ph;
- (10) -SO₂NH₂, -SO₂NMe₂, -SO₂NEt₂;
- (11) -NMe₂, -NEt₂;
- (12) morpholino;
- (13) -NO₂;
- (14) -CN.








167. (Previously Presented) A compound according to claim 80, selected from the following compounds, and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof:




































































168. (Previously Presented) A composition comprising a compound according to claim 80 and a pharmaceutically acceptable carrier.

169. (Previously Presented) A method inhibiting HDAC in a cell comprising said cell with an effective amount of a compound according to claim 80.

170. (Previously Presented) A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound according to claim 80.

171. (Previously Presented) A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to claim 80.

172. (Previously Presented) A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to claim 80.

173. (Previously Presented) A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to claim 80.